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Ulf Kallweit1*, Kosuke Aritake2, Claudio L Bassetti1, Stephan Blumenthal3, Osamu Hayaishi2, Michael Linnebank1,
Christian R Baumann1 and Yoshihiro Urade2Abstract
Background: Histamine is an ubiquitous inflammatory mediator of numerous physiological processes. Histamine
and its receptors have been implicated in multiple sclerosis (MS) disease pathogenesis. We prospectively enrolled
36 MS patients and 19 age and gender-matched healthy volunteers for cerebrospinal fluid (CSF) histamine analysis.
Findings: CSF histamine levels in MS patient samples were significantly higher (median: 35.6 pg/ml) than in
controls (median: 5.5 pg/ml; Beta = 0.525, p < 0.001). In addition, histamine increased with age (Pearson’s correlation,
p < 0.003).
Conclusions: Histamine may be an important factor for both the initiation and maintenance of chronic
inflammatory diseases of the central nervous system. Our observation encourages a deeper investigation of the role
of histamine in MS.
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Multiple sclerosis (MS) is a complex autoimmune dis-
ease with inflammation and demyelination within the
central nervous system (CNS). Histamine and its recep-
tors have been implicated in MS disease pathogenesis
[1]. Histamine is an ubiquitous inflammatory mediator
of numerous physiological processes including local im-
mune responses and allergic reactions, and it plays an
important role in neurotransmission. The functions of
histamine are mediated through 4 G-protein coupled re-
ceptors (H1-H4 receptors). Histamine and histamine re-
ceptors play a regulatory role in experimental allergic
encephalomyelitis (EAE), the animal model of MS [1-3].
Rodent experiments revealed that histamine increases
the permeability of the blood brain barrier, promoting
CNS inflammation [1,4,5]. The cytokine granulocyte-
macrophage colony-stimulating factor (GM-CSF) in
auto-reactive T helper cells is mandatory to induce and
sustain EAE in mice [6]. GM-CSF stimulates granulocytes
and macrophages, and both secrete histamine. A small* Correspondence: ulf.kallweit@ usz.ch
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reproduction in any medium, provided the orstudy by Tuomisto et al. [7], reported on higher CSF hista-
mine level by about 60% both in patients with remitting
and progressive type of MS than in controls. Based on this
observation and previous studies in EAE, we hypothesized
that histamine might play a role in MS. Thus, we aimed at
testing whether histamine is elevated in the CSF of MS
patients.
Findings
Methods
We prospectively enrolled consecutive 36 MS patients
(mean (±SD) age, 51 ± 10 years; 64% female; 24 patients
with secondary progressive disease, 12 relapsing-
remitting, RRMS) of Caucasian origin treated in the MS
center of the University Hospital Zurich and 19 age and
gender-matched healthy volunteers: age 46 ± 10 years
(mean ±SD); 37% female. In all patients, the diagnosis of
MS was made according to the McDonald diagnostic
criteria 2005 [8]. We enrolled all types of MS. Lumbar
puncture was performed for diagnostic purposes. In 19
patients, LP was performed for diagnosis of MS and in
17 secondary progressive MS (SPMS) patients for
evaluation of treatment effects of first-time intrathecal
baclofen (N = 7) or triamcinolone acetonid (N = 10) ap-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Boxplot of cerebrospinal fluid histamine levels in 36
patients with MS and in 19 healthy controls. The horizontal solid
line depict median levels per group. The bottom of the box
represents the 25th percentile, the top of the box the 75th percentile.
T-bars represent the lowest datum still within 1.5 interquartile range
(IQR) of the lower quartile, and the highest datum still within 1.5 IQR
of the upper quartile. Dots and stars represent extreme outliers
(each symbol represents one patient).
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ascertained during spinal anesthesia. Subjects with signs
of neurological or sleep-wake disorders were not
included as controls. Patients and controls suffering
from any allergic disease were not included into this
study. All patients and healthy controls gave informed
written consent. The study was approved by the local
ethics committee.
Routine CSF analysis included oligoclonal bands and
IgG index. For histamine analysis, after assessment of
CSF, samples were immediately centrifuged, put on dry
ice and stored at −80°C until assay. Storage was between
6 and 24 months (patients and controls). As far as we
examined, histamine contents in biological samples
stored at −80°C did not change over 2 years. Samples
were separated by high-performance liquid chromatog-
raphy (HPLC), thereafter histamine was post-labeled by
O-phthalaldehyde and detected by fluorometric analysis
[9]. HPLC has been used for the measurement of hista-
mine in CSF in other neurological disorders [10].
Statistical analyses were performed with SPSS 19.0.
Group data are described by median. For the compari-
son of parametric data, we Student’s t-tests, and for
non-parametric data, Whitney U-test was used. For
correlation analyses in parametric data, we used
Pearson’s correlation. To control for effects of sex, age
and different types of MS on histamine concentrations,
we ran multivariate logistic regression analyses.Results
RRMS patients received disease modifying therapies
(DMT): Interferon-beta 1a- i.m. (Avonex, N = 4),
Interferon-beta 1a, s.c. (Rebif, N = 4), Glatirameracetat s.c.
(Copaxone, N = 3), Natalizumab 300 mg i.v. (Tysabri,
N = 1). In SPMS patients, 4 patients received DMT (Inter-
feron-beta 1a, s.c. (Rebif, N = 2), Mitoxantrone i.v. (N = 2).
Previously all SPMS patients were treated by at least
one DMT. CSF histamine levels in patient samples are
shown in the boxplot in Figure 1. After exclusion of the
two each outliers, histamine levels in patients (median:
35.6 pg/ml) were significantly higher than in controls
(median: 5.5 pg/ml; Beta = 0.525, p < 0.001). Also with-
out exclusion of outliers, this difference was significant
(p < 0.017). In addition, histamine increased with age
(Pearson’s correlation, p < 0.003), but were similar in
men (30.0 ± 27.0) and women (39.2 ± 6.4; t = 0.89;
p < 0.381) and were not associated with diagnosis of
relapsing remitting (26.0 ± 28.2) versus secondary
progressive MS (39.9 ± 31.6; t = 1.5; p < 0.154). No cor-
relations were found between CSF histamine levels and
the results of other CSF analyses, (e.g. IgG index),
treated and non-treated patients or existing DMT (data
not shown).Discussion
This study confirmed results by Tuomisto [7] and our
hypothesis that histamine levels are increased in MS
patients. Histamine functions are not only limited to
allergic functions but are extended to other processes
related to neurology, immunology, or oncology [11].
Until now, no CNS disease entity has been associated
directly with brain histamine dysfunction, but different
histamine receptors [H(3), H(4)] are recognized as drug
targets for (e.g.) sleep-wake disorders, Parkinson’s
disease, and neuroimmunopharmacology [12].
Histamine in CSF originates from mast cells and hista-
minergic neurons of the tuberomammillary nucleus of
the posterior basal hypothalamus [13]. The GM-CSF
-mediated stimulation of granulocytes and macrophages
may be one possible underlying mechanism for elevated
histamine levels in MS. Thus histamine may be an
important factor for both the initiation and maintenance
of chronic inflammatory diseases of the central nervous
system such as MS. This interpretation remains theore-
tical until data from other patient groups with acute and
chronic inflammatory and non-inflammatory diseases of
the CNS confirm our results.
Limitations of our study include the small study size
and the large intra-group variability of histamine levels.
We did not measure histamine levels in blood. Although
peripheral histamine hardly enters into CNS through
blood brain barrier [14,15], we cannot completely
exclude the possibility that histamine concentrations in
CSF are not only controlled in brain, but also derive
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effects on histamine levels.
Conclusions
This observation encourages a deeper investigation of
the role of GM-CSF, granulocytes, macrophages and
histamine in MS. Further, histamine may be investigated
as diagnostic marker for MS and other inflammatory
CNS diseases.
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